Form 8-K
8-K — VSEE HEALTH, INC.
Accession: 0001185185-26-002359
Filed: 2026-06-05
Period: 2026-05-31
CIK: 0001864531
SIC: 8000 (SERVICES-HEALTH SERVICES)
Item: Entry into a Material Definitive Agreement
Item: Completion of Acquisition or Disposition of Assets
Item: Unregistered Sales of Equity Securities
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Financial Statements and Exhibits
Documents
8-K — vsee8k060526.htm (Primary)
EX-10.1 — EXHIBIT 10.1 (vseeex10-1.htm)
EX-99.1 — EXHIBIT 99.1 (vseeex99-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: vsee8k060526.htm · Sequence: 1
false
0001864531
0001864531
2026-05-31
2026-05-31
0001864531
VSEE:CommonStock0.0001ParValuePerShareMember
2026-05-31
2026-05-31
0001864531
VSEE:WarrantsWhichEntitlesHolderToPurchaseOne1ShareOfCommonStockAtPriceOf11.50PerWholeShareMember
2026-05-31
2026-05-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 5, 2026 (May 31, 2026)
VSEE
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-41015
86-2970927
(State
or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S.
Employer
Identification No.)
980
N Federal Hwy #304
Boca Raton, Florida
33432
(Address
of principal executive offices)
(Zip
Code)
Registrant’s
telephone number, including area code: (561) 672-7068
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title
of each class
Trading
Symbol
Name
of each exchange on
which registered
Common
Stock, $0.0001 par value per share
VSEE
The
Nasdaq Stock Market LLC
Warrants,
which entitles the holder to purchase one (1) share of common stock at a price of $11.50 per whole share
VSEEW
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry
into a Material Definitive Agreement.
On
May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase
Agreement”) with Milton Chen, the Company’s co-Chief Executive Officer and Chairman of the Board and the Chief Executive
Officer of VSee Lab, Inc., a Delaware Corporation and wholly-owned subsidiary of the Company (“VSee Lab”). Pursuant to the
Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell to Mr. Chen, on the May 31, 2026 (the “Closing
Date”), all of the equity securities of VSee Lab (the “VSee Lab Stock”), free and clear of all liens and encumbrances.
Under the Purchase Agreement, Mr. Chen is solely responsible for causing the Company to satisfy any and all indebtedness and other liabilities
of VSee Lab that are not paid as of the closing contemplated by the Purchase Agreement (the “Closing”) and the Company will
have no obligation with respect thereto. Notwithstanding, the Company will retain, pay, perform and discharge and remain solely responsible
for, any and all liabilities, obligations or commitments of VSee Lab or relating to the ownership or operation of VSee Lab related to
any period, event, circumstance or condition occurring prior to the Closing Date, including any liabilities relating to taxes for any
and all taxes attributable to any taxable period ending on or before the Closing Date and the portion through the Closing Date for any
taxable period that includes, but does not end, on the Closing Date, other than sales and use taxes accrued at the company level, which
will remain an obligation of VSee Lab, regardless of the time period of when such obligation were incurred and except to the extent expressly
assumed by Mr. Chen pursuant to the Purchase Agreement.
In
consideration for the VSee Lab Stock and the mutual release of liability set forth in the Purchase Agreement, Mr. Chen has agreed to
transfer to the Company all of the common stock, par value $0.0001 per share (the “Common Stock”), of the Company that he
currently owns, or 2,870,069 shares of Common Stock. In connection with the execution of the Purchase Agreement, Mr. Chen resigned as
co-Chief Executive Officer and chairman of the board of directors of the Company, effective as of the Closing Date.
The
foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the
Purchase Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
2.01 Completion
of Acquisition or Disposition of Assets
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 2.01.
Filed
as Exhibit 99.1 to this Current Report on Form 8-K is the unaudited pro forma condensed consolidated balance sheet of the Company as
of March 31, 2026 and the unaudited pro forma condensed consolidated statements of operations of the Company for the three months ended
March 31, 2026, and the year ended December 31, 2025, in each case giving effect to the transaction described under Item 1.01 of this
Current Report on Form 8-K.
Item
3.02 Unregistered
Sales of Equity Securities.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02.
The
Common Stock to be issued in the connection with the Purchase Agreement will be issued in transactions exempt from registration under
Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated
thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2)
of the Securities Act, and other applicable requirements were met. Neither this Current Report on Form 8-K nor any of
the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy the shares of Common Stock or any other securities
of the Company.
Item
5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 5.02.
Mr. Chen’s resignation was not because of any
disagreement between Mr. Chen and the Company on any matter relating to the Company’s operations, policies or practices. Concurrently
with Mr. Chen’s resignation, Dr. Imoigele Aisiku, the Company’s co-Chief Executive Officer, was appointed as the sole Chief
Executive Officer and the chairman of the board of directors of the Company, effective immediately.
Item
9.01 Financial
Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
Description
10.1
Stock Purchase Agreement, dated May 31, 2026, by and between VSee Health, Inc. and Milton Chen.
99.1
Unaudited pro forma condensed consolidated balance sheet of VSee Health Inc. as of March 31, 2026, and the unaudited pro forma condensed consolidated statements of operations of VSee Health Inc. for the three months ended March 31, 2026, and the year ended December 31, 2025.
104
Cover
Page Interactive Data File (embedded within the Inline XBRL document)
1
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated:
June 5, 2026
VSEE
HEALTH, INC.
By:
/s/
Imoigele Aisiku
Name:
Imoigele
Aisiku
Title:
Chief
Executive Officer
2
EX-10.1 — EXHIBIT 10.1
EX-10.1
Filename: vseeex10-1.htm · Sequence: 2
Exhibit 10.1
STOCK
PURCHASE AGREEMENT
This
STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of May 31, 2026, by and between VSee Health, Inc., a Delaware
corporation (“VSee Health”) and Milton Chen, an individual (“Chen” and, together with VSee Health,
the “Parties” and, each individually, a “Party”).
RECITALS
WHEREAS,
VSee Health owns one hundred percent (100%) of the equity securities (the “Company Stock”) of VSee Lab, Inc., a Delaware
corporation (the “Company”), which was founded by Chen in 2008 and acquired by VSee Health in 2022;
WHEREAS,
the Parties acknowledge that Chen is a founder of the Company and is entering into this Agreement in connection with a negotiated separation
and restructuring of ownership and management of the Company;
WHEREAS,
Chen (a) owns 2,870,069 shares of common stock of VSee Health, par value $0.0001 per share (the “Chen VSee Stock”)
and (b) is the (i) co-chief executive officer and chairman of the board of VSee Health and (ii) chief executive officer of the Company;
WHEREAS,
VSee Health desires to sell, and Chen desires to purchase, all of the Company Stock, upon the terms and subject to the conditions herein
provided; and
WHEREAS,
the Parties intend that, effective as of the Closing, the Company shall operate as an independent standalone business, separate and apart
from VSee Health and its affiliates, with all necessary assets, rights, systems, and personnel to conduct its business on a going-forward
basis;
NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Parties agree as follows:
ARTICLE
I
PURCHASE AND SALE
1.1 Transaction.
Subject to the terms and conditions set forth in this Agreement, Chen hereby agrees to purchase from VSee Health, and VSee Health hereby
agrees to sell, convey, assign, transfer and deliver to Chen, on the Closing Date (as defined below), all of VSee Health’s right,
title and interest in and to the Company Stock, free and clear of all liens and encumbrances (other than restrictions imposed by applicable
securities laws). For the avoidance of doubt, following the Closing, Chen shall be solely responsible for causing the Company to satisfy
any and all indebtedness and other liabilities of the Company that are not paid as of the Closing and VSee Health shall have no obligation
with respect thereto. Notwithstanding anything herein to the contrary, VSee Health shall retain, pay, perform and discharge, and shall
remain solely responsible for, any and all liabilities, obligations or commitments of the Company or relating to the ownership or operation
of the Company arising out of, relating to or attributable to any period, event, circumstance or condition occurring on or prior to the
Closing Date, including any liabilities relating to taxes for any Pre-Closing Tax Period (defined below), other than sales and use taxes
accrued at the Company level, which shall remain an obligation of the Company, regardless of the time period such liabilities were incurred,
and except to the extent expressly assumed by Chen pursuant to this Agreement.
1.2 Consideration.
In consideration for the Company Stock and the mutual release set forth in Section 4.2, at Closing, Chen shall transfer to VSee
Health one hundred percent (100%) of the Chen VSee Stock.
- 1 -
1.3 Closing.
The closing of the transactions contemplated hereby (the “Closing”) shall take place by electronic exchange of documents
on the date hereof (the “Closing Date”). The Closing will be deemed effective as of 11:59 P.M. (Eastern Time) on the
Closing Date.
1.4 Intercompany
Accounts. Effective as of the Closing, all intercompany accounts, loans, advances, payables, receivables, obligations or balances
between VSee Health or any of its affiliates, on the one hand, and the Company, on the other hand, shall be deemed satisfied, cancelled
and discharged in full, and neither VSee Health nor any of its affiliates shall have any further claim with respect thereto following
the Closing.
ARTICLE
II
REPRESENTATIONS AND WARRANTIES OF VSEE HEALTH
VSee
Health represents and warrants to Chen as follows:
2.1 Due
Organization; Good Standing. VSee Health is a corporation duly organized, validly existing and in good standing under the laws of
the State of Delaware, and VSee Health has the corporate power and authority to carry on its business as now conducted, to own and operate
the properties and assets which comprise VSee Health (including the Company Stock) now owned and operated by it and to enter into and
perform this Agreement.
2.2 Corporate
Authorization; Binding Effect.
(a) VSee
Health has all requisite corporate power and authority to execute and deliver this Agreement and to perform fully its obligations hereunder
and to consummate the transactions contemplated hereby. The execution, delivery and performance of this Agreement by VSee Health, and
the transfers, conveyances, assignments, deliveries and other agreements to be executed by VSee Health pursuant hereto or in connection
herewith, have been duly authorized by all necessary corporate action.
(b) This
Agreement is a valid and legally binding obligation of VSee Health, enforceable against VSee Health in accordance with its terms, and
each agreement, document and instrument contemplated by this Agreement, when executed and delivered by VSee Health in accordance with
the provisions of this Agreement, will be valid and legally binding obligations of VSee Health, enforceable in accordance with their
respective terms.
2.3 Governmental
Approvals; Non-Contravention.
(a) No
consent, approval, filing or notice with any governmental entity or other person is required for VSee Health to execute, deliver or perform
this Agreement.
(b) VSee
Health’s execution, delivery and performance of this Agreement and consummation of the transactions described herein, shall not
(i) violate any applicable law or order, (ii) breach or default under any contract binding upon VSee Health or the Company Stock, (iii)
create any lien on the Company Stock or Company’s assets, or (iv) result in any “stop transfer” instructions affecting
the Company Stock.
2.4 Ownership
of Company Stock. VSee Health owns, beneficially and of record and has good and valid title to the Company Stock, free and clear
of all liens and encumbrances (other than restrictions imposed by applicable securities laws). At the Closing, VSee Health will convey
to Chen all of VSee Health’s right, title and interest in and to the Company Stock, free and clear of all liens (other than liens
imposed by applicable securities laws). Except in connection with this Agreement, VSee Health has not sold, or granted any options or
rights to purchase, and VSee Health has not entered into any contract or other agreement obligating VSee Health to sell or grant options
or rights to purchase, any of such Company Stock, except to Chen.
- 2 -
2.5 Solvency.
VSee Health is not entering into this Agreement with the intent to hinder, delay or defraud any creditor, and the consummation of the
transactions contemplated hereby will not render VSee Health insolvent.
ARTICLE
III
REPRESENTATIONS
AND WARRANTIES OF CHEN
Chen
hereby represents and warrants to VSee Health as follows:
3.1 Capacity
and Authorization of Chen. Chen is a natural person with the legal capacity to execute and deliver this Agreement and to perform
his obligations hereunder.
3.2 Authorization;
Binding Effect. This Agreement is a valid and legally binding obligation of Chen, enforceable against him in accordance with its
terms, and the other agreements, documents and instruments contemplated by this Agreement, when executed and delivered by Chen in accordance
with the provisions of this Agreement, will be duly authorized, executed and delivered by Chen and will be valid and legally binding
obligations of Chen, enforceable in accordance with their respective terms.
3.3 Knowledgeable
Party. Chen is fully familiar with the business, financial condition and prospects of the Company, and realizes that the acquisition
of the Company Stock is a speculative investment involving a high degree of risk for which there is no assurance of any return.
Chen acknowledges that the value of the Company Stock may significantly appreciate or depreciate over time. Chen has had the opportunity
to discuss the Company’s business and financial affairs, and all documents affecting the Company generally, with the members of
VSee Health’s management. Except for the representations and warranties expressly set forth in this Agreement, Chen acknowledges
that he has not relied upon any representation or warranty of VSee Health or any of its representatives regarding the Company or the
value of the Company Stock. Chen understands that VSee Health will rely on the accuracy and truth of the foregoing representations, and
Chen hereby consents to such reliance.
3.4 Governmental
Approvals; Non-Contravention.
(a) No
consent, approval, filing or notice with any governmental entity is required for Chen to execute, deliver or perform this Agreement.
(b) Chen’s
execution, delivery and performance of this Agreement and consummation of the transactions described herein, will not violate any applicable
law or order.
3.5 Ownership
of Chen VSee Stock. Chen owns, beneficially and of record and has good and valid title to the Chen VSee Stock, free and clear of
all liens (other than liens imposed by applicable securities laws). At Closing, Chen will convey to VSee Health all of Chen’s right,
title and interest in and to the Chen VSee Stock, free and clear of all liens (other than liens imposed by applicable securities laws).
Except in connection with this Agreement, Chen has not sold, or granted any options or rights to purchase, and Chen has not entered into
any contract or other agreement obligating Chen to sell or grant options or rights to purchase, any of such Chen VSee Stock, except to
VSee Health.
- 3 -
3.6 Securities
Law Matters. Chen represents that he is aware of his obligations under applicable securities laws in connection with the transfer
of the Chen VSee Stock and has not entered into this Agreement on the basis of material non-public information in violation of applicable
securities laws.
ARTICLE
IV
INDEMNIFICATION, RELEASE AND OTHER AGREEMENTS
4.1 Indemnification.
(a) VSee
Health hereby agrees to defend, indemnify and hold Chen harmless from and against any and all liabilities, losses, damages, costs, judgments
or expenses (including, without limitation, reasonable attorneys’ and accountants’ fees and expenses, court costs and all
other out-of-pocket expenses) (collectively, “Losses”) incurred by Chen (i) arising out of or in connection with the
breach of any warranty or the inaccuracy of any representation by VSee Health contained in this Agreement and (ii) arising out of or
in connection with any failure by VSee Health to perform any of the covenants, agreements or obligations under this Agreement or any
other agreement or instrument executed and delivered by or on behalf of VSee Health pursuant hereto or in connection herewith and (iii)
which consist of or relate to the operation of the Company or VSee Health prior to the Closing Date.
(b) Chen
hereby agrees to defend, indemnify and hold VSee Health and its officers, directors, shareholders and affiliates (collectively, the “VSee
Health Indemnified Parties”) harmless, from and against any and all Losses incurred by any VSee Health Indemnified Party (i)
arising out of or in connection with the breach of any warranty or the inaccuracy of any representation by Chen contained in this Agreement
and (ii) arising out of or in connection with any failure by Chen to perform any of its covenants, agreements or obligations under this
Agreement or any other agreement or instrument executed and delivered by or on behalf of Chen pursuant hereto or in connection herewith
and (iii) which consist of or relate to the operation of the Company after the Closing Date.
(c) Claims
and Litigation. In the event that any person or entity not a party to this Agreement shall make any demand or claim, or file or threaten
to file any lawsuit, which demand, claim or lawsuit may result in any Loss to either Chen on the one hand, or a VSee Health Indemnified
Party on the other (each hereinafter an “Indemnified Party”) for which such Indemnified Party may seek indemnity from
the other Party hereunder (the “Indemnifying Party”), then, the Indemnified Party shall give prompt written notice
to such Indemnifying Party of such demand, claim or lawsuit, and such Indemnifying Party shall have the option at its cost and expense,
to join in the defense of any such demand, claim or lawsuit, and no such claim shall be settled or compromised without the consent (which
shall not be unreasonably withheld, conditioned or delayed) of such Indemnifying Party, unless such Indemnifying Party shall fail to
respond within ten (10) days after receipt of such notice of any such demand, claim or lawsuit, or shall notify the Indemnified Party
that it does not intend to defend such demand, claim or lawsuit. The Indemnifying Party, in the defense of any such demand, claim or
lawsuit, shall not, except with the consent (which shall not be unreasonably withheld, conditioned or delayed) of the Indemnified Party,
consent to entry of any judgment or entry into any settlement which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to the Indemnified Party or a release from all liability in respect to such claim or litigation. Nothing contained
in this Section 4.1(c) shall prevent any Indemnified Party from taking such action as may be necessary prior to the end of the
ten (10) day period provided for above to prevent a default judgment from being entered.
(d) Attorneys’
Fees, Interest, Penalties, Costs and Expenses. Each of the Indemnified Parties’ right of indemnity hereunder shall extend to
all interest, penalties, costs and expenses, including reasonable attorneys’ fees, incident to any of the matters covered by Section
4.1(a) and 4.1(b) hereof.
- 4 -
(e) Survival;
Limitations.
A. The
representations and warranties contained in this Agreement shall survive the Closing for a period of eighteen (18) months following the
Closing Date; provided, however, that the representations and warranties contained in Sections 2.1, 2.2, 2.4, 3.1,
3.2 and 3.5 (collectively, the “Fundamental Representations”) shall survive indefinitely.
B. No
Party shall be liable for indemnification under this Agreement unless the aggregate amount of Losses exceeds $25,000, in which case the
Indemnifying Party shall be liable only for Losses in excess of such amount.
C. Except
in the case of fraud or intentional misconduct, the aggregate liability of Chen under this Agreement shall not exceed the value of the
Chen VSee Stock transferred pursuant hereto. For purposes of this Agreement, “fraud” means actual and intentional
common law fraud and shall not include constructive fraud, equitable fraud or negligent misrepresentation.
D. In
no event shall either Party be liable for punitive, consequential or special damages except to the extent payable to a third party.
(f) Pre-Closing
Taxes. VSee Health shall indemnify and hold harmless Chen and the Company from and against any and all taxes attributable to any
taxable period ending on or before the Closing Date and the portion through the Closing Date for any taxable period that includes, but
does not end, on the Closing Date, other than sales and use taxes accrued at the Company level, which shall remain an obligation of the
Company, regardless of the time period such liabilities were incurred (the “Pre-Closing Tax Period”), together with
any interest, penalties or additions thereto. VSee Health shall control any audit, contest or proceeding relating to such taxes; provided,
that, Chen or the Company shall have the right to participate therein at their own expense.
4.2 Mutual
Release.
(a) Effective
of the Closing, each of (i) Chen, on behalf of himself, his affiliates and their respective members, officers, managers, directors, employees,
successors and assigns (collectively, the “Chen Releasors”), and (ii) VSee Health, on behalf of itself, its affiliates,
officers, managers, directors, employees, agents, representatives, successors and assigns (collectively, the “VSee Releasors”
and, together with the Chen Releasors, the “Releasors”), hereby mutually releases, waives, and forever discharges
the other Party and each of their respective present and former members, shareholders, partners, parents, subsidiaries, affiliates, officers,
managers, directors, employees, agents, representatives, successors and assigns (collectively, the “Releasee(s)”)
of and from any and all actions, causes of action, suits, losses, liabilities, rights, debts, dues, sums of money, accounts, reckonings,
obligations, costs, expenses, liens, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances,
trespasses, breaches, damages, judgments, extents, executions, claims, and demands, of every kind and nature whatsoever, whether now
known or unknown, foreseen or unforeseen, fixed or contingent, matured or unmatured, suspected or unsuspected, in law or equity (collectively,
the “Claims”), which any Releasor ever had, now has, or hereafter can, shall, or may have against any Releasee for,
upon, or by reason of any matter, cause, or thing whatsoever from the beginning of time arising from any event that occurred prior to
the Closing. Notwithstanding anything herein to the contrary, nothing in this Section 4.2(a) shall release, waive, discharge or
otherwise affect (i) the rights or obligations of any Party under this Agreement or any other written agreement entered into in connection
herewith, (ii) any rights to indemnification, advancement of expenses or insurance coverage, whether arising under contract, organizational
documents, applicable law or otherwise, or (iii) any claims arising from fraud or intentional misconduct.
- 5 -
(b) Each
of Chen, on behalf of himself and the other Chen Releasors, and Vsee Health, on behalf of itself and the other VSee Releasors, intends
to, and does hereby, fully, finally, and forever settle and release all Claims that now exist, may exist, or previously existed, whether
known or unknown, foreseen or unforeseen, or suspected or unsuspected, and the release given herein is and will remain in effect as a
complete release, notwithstanding the discovery or existence of any additional or different facts.
(c) Each
Releasee shall be a third-party beneficiary of this Section 4.2.
4.3 Termination
of Employment Agreement; Resignations. By executing this Agreement:
(a) the
Parties agree that Chen’s employment with VSee Health is terminated, effective as of the Closing Date; and
(b) Chen
hereby resigns, and VSee Health hereby accepts Chen’s resignation, (i) as chairman of the board of directors of VSee Health, (ii)
as co-chief executive officer of VSee Health and (iii) from any and all other positions Chen holds with VSee Health and its subsidiaries
(other than the Company), including, without limitation, any positions as an officer or an authorized person, in each case effective
as of the Closing Date.
4.4 Confidentiality.
Each Party acknowledges that it may be in possession of confidential and other proprietary information concerning VSee Health and the
Company (collectively, “Confidential Information”). Upon the Closing and continuing thereafter, the Parties shall,
and shall cause their affiliates, advisors and representatives to treat confidentially and not disclose all or any portion of such Confidential
Information. Each Party and their respective affiliates and representatives may disclose Confidential Information only for purposes of
(a) compliance with any agreement between such Party or any of its affiliates or representatives; (b) compliance with any request by
the other Party or its affiliates; (c) compliance with any applicable law or order, or (d) in connection with a dispute or any tax proceeding
regarding the amount of any tax imposed on a such Party, as applicable, or the preparation of any tax return related to any such tax;
provided, that, with respect to any request for disclosure made pursuant to clauses (c) and (d) above, such disclosing Party shall,
if legally permitted to do so, provide the other Party with prompt written notice of such request so that the non-disclosing Party may
seek an appropriate protective order or other appropriate remedy at such non-disclosing Party’s sole cost and expense. At any time
that such protective order or remedy has not been obtained, the disclosing Party (or its affiliates and representatives) may disclose
only that portion of the Confidential Information which such disclosing Party is legally required to disclose or of which disclosure
is required to avoid sanction for contempt or any similar sanction, and each disclosing Party shall exercise its or his commercially
reasonable efforts to obtain assurance that confidential treatment will be accorded to such Confidential Information so disclosed.
4.5 Insurance
Coverage. Nothing in this Agreement shall limit, impair, waive or otherwise adversely affect any rights of Chen to indemnification,
advancement of expenses or coverage under any existing directors’ and officers’ liability insurance policy maintained by
VSee Health with respect to any act, omission, event or circumstance occurring during Chen’s service as an officer or director
of VSee Health or the Company.
4.6 Books
and Records. At the Closing, VSee Health shall deliver or make available to Chen all books and records of the Company in its possession
or control, including corporate records, financial statements, tax records, personnel records, customer and vendor information, contracts
and other business records reasonably necessary for the continued operation of the Company. Following the Closing, each Party shall provide
the other reasonable access to such books and records as may be reasonably requested in connection with tax matters, litigation or compliance
with applicable law.
- 6 -
4.7 Transition
Assistance. For a period of 180 days following Closing (i) VSee Health shall reasonably cooperate with Chen in transitioning the
Company, including making available relevant records, systems access, and assistance reasonably requested by Chen to ensure continuity
of operations and (ii) the Company and Chen shall reasonably cooperate with VSee Health by providing any relevant records, systems access,
and assistance reasonably requested by VSee Health in connection with the preparation of financial statements up to and including the
Closing Date.
4.8 Transition
Services. To the extent the Company requires any services from VSee Health or its affiliates following the Closing, such services
shall be provided only pursuant to a mutually agreed transition services agreement (the “TSA”) with defined scope,
duration, and compensation. Except as expressly set forth in the TSA, neither Party shall have any obligation to provide ongoing services
to the other.
4.9 Systems
and Data Separation. Prior to or as of the Closing, VSee Health shall cause all information technology systems, cloud environments,
domain names, databases, and third-party service accounts used by the Company (to the extent such are registered to VSee Health) to be
separated from VSee Health’s systems and transferred or re-registered in the name of the Company, or otherwise made independently
accessible by the Company without reliance on VSee Health systems.
4.10 Business
Continuity. Following the Closing, VSee Health shall not take any action intended to interfere with, disrupt or redirect the Company’s
relationships with its customers, vendors, or employees, and shall reasonably cooperate to maintain continuity of such relationships,
and neither the Company nor Chen shall take any action intended to interfere with, disrupt or redirect the VSee Health’s relationships
with its customers, vendors, or employees, and shall reasonably cooperate to maintain continuity of such relationships.
4.11 No
Implied Licenses. Except as expressly set forth herein, nothing in this Agreement shall be deemed to grant either Party any license
or other rights in or to any intellectual property of the other Party.
4.12 No
Continuing Control; Clean Break. From and after the Closing, VSee Health shall have no right to direct or control the operations,
management, or business decisions of the Company, and the Company shall operate as an independent entity. Except as expressly set forth
in this Agreement or any ancillary agreement, the Parties acknowledge and agree that the transactions contemplated hereby are intended
to constitute a full and complete separation of the Company from VSee Health, and neither Party shall have any continuing obligation
to the other following the Closing.
4.13 Public
Announcements. Neither Party shall issue any press release or public announcement regarding this Agreement or the transactions contemplated
hereby without the prior written consent of the other Party, except as required by applicable law, stock exchange requirements or SEC
rules. To the extent disclosure is required, the disclosing Party shall, to the extent legally permissible, provide the other Party with
a reasonable opportunity to review and comment on such disclosure prior to publication.
4.14 Filings
and Registrations. Following the Closing, each Party shall be responsible for its own regulatory filings, registrations and compliance
obligations, and shall cooperate as reasonably necessary to effectuate the separation of the Company from VSee Health for all regulatory
and tax purposes.
- 7 -
ARTICLE
V
DELIVERABLES
5.1 At
Closing:
(a) Chen
shall have delivered or caused to be delivered to VSee Health’s transfer agent the stock certificates evidencing ownership of the
Chen VSee Stock, duly endorsed in blank or accompanied by stock powers or other instruments of transfer duly executed in blank and with
all required stock transfer tax stamps affixed.
(b) VSee
Health shall have delivered or caused to be delivered to Chen stock certificates evidencing the Company Stock, duly endorsed in blank
or accompanied by stock powers or other instruments of transfer duly executed in blank and with all required stock transfer tax stamps
affixed.
(c) If
any of the shares of the Chen VSee Stock or the Company Stock are uncertificated or otherwise not represented by physical stock certificates,
then at Closing, such shares shall be transferred by appropriate book-entry notation on the books and records of the relevant Party (or
its respective transfer agent, as applicable), and promptly following such transfer the transferring Party shall deliver, or cause to
be delivered, to the other Party a written statement or other customary evidence reflecting the transfer of ownership of such shares.
(d) VSee
Health shall deliver all passwords, access credentials, administrator rights, source code repositories, domain registrations and other
access rights necessary for the operation of the Company.
ARTICLE
VI
MISCELLANEOUS
6.1 Entire
Understanding; Amendment. This Agreement and the other agreements and instruments referenced herein and delivered in connection herewith,
represent the entire understanding of the Parties with respect to the subject matter hereof and supersede all prior and contemporaneous
negotiations, understandings and agreements, written or oral, among the Parties hereto with respect to the subject matter hereof, all
of which prior agreements are hereby rendered null and void. This Agreement may not be amended or modified except by a writing executed
by each of the Parties.
6.2 Non-Disparagement.
The Parties agree that they shall not knowingly make any false, misleading or disparaging statements regarding the other Party or any
of their respective affiliates, officers, directors, employees or agents. Nothing herein shall prohibit truthful testimony or disclosures
required by applicable law. The Parties acknowledge that a breach of this Section 6.2 may result in irreparable harm for which
monetary damages may be inadequate and that injunctive relief may therefore be available.
6.3 Independent
Relationship. Following the Closing, nothing in this Agreement shall be construed to create any partnership, joint venture, agency
or fiduciary relationship between the Parties.
6.4 Further
Assurances. Chen and VSee Health each agree that they shall, at any time and from time to time after the Closing Date, upon request
of the other Party, do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered, such further acts,
deeds, assignments, transfers, conveyances and assurances as may be reasonably necessary to further effectuate the terms of this Agreement.
- 8 -
6.5 Binding
Effect. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted
assigns.
6.6 Assignment.
Neither Party hereto may assign this Agreement without the prior written consent of the other Party.
6.7 Counterparts.
This Agreement may be signed in counterparts, each of which shall be considered an original and together they shall constitute one agreement.
Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act
of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes.
6.8 Section
Headings; Exhibits; Schedules. Section headings contained in this Agreement are for convenience or reference only and shall not be
deemed a part of this Agreement.
6.9 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its
conflict of laws rules.
6.10 No
Setoff. Neither Party shall have any right of setoff, counterclaim or deduction against any obligations hereunder except as expressly
set forth in this Agreement or agreed in writing by the other Party.
6.11 Dispute
Resolution. Any dispute arising out of or relating to this Agreement shall be resolved by confidential arbitration administered by
JAMS in Wilmington, Delaware pursuant to its Comprehensive Arbitration Rules. The arbitrator shall have authority to award equitable
relief, including injunctive relief. Each Party shall bear its own attorneys’ fees and costs, except as otherwise awarded by the
arbitrator. The Parties may seek temporary or preliminary injunctive relief from a court of competent jurisdiction pending appointment
of the arbitrator.
6.12 Waiver
of Jury Trial. THE PARTIES HEREBY WAIVE ANY AND ALL RIGHTS THEY MAY HAVE TO TRIAL BY A JURY WITH REGARD TO ANY CLAIM OR DISPUTE.
To the extent that this provision is ruled to be unenforceable for any reason, the Parties agree that a court of competent jurisdiction
be allowed to blue-pencil this provision so that it comports with said court’s concerns while still giving effect to the Parties’
intent to arbitrate any disputes arising between them.
6.13 No
Waiver. No failure of either Party to exercise any right hereunder or to insist upon strict compliance by the other with any obligation
or provision hereunder, and no custom or practice of the Parties at variance with the terms hereunder shall constitute a waiver of the
right to demand exact compliance with the terms hereof. Waiver by a non-defaulting Party of any right arising from a default of the other
Party shall not affect or impair the rights of the non-defaulting Party with respect to any subsequent default by the other Party of
the same or of a different nature.
6.14 Attorneys’
Fees. If any action at law or in equity permitted under this Agreement, including actions to compel arbitration or enforce an arbitration
award, is necessary to enforce or interpret the terms of this Agreement, the prevailing Party shall be entitled to reasonable attorneys’
fees, costs and necessary disbursements in addition to such other relief to which such Party may be entitled.
6.15 Notices.
All notices, requests, demands and other communications hereunder shall be in writing and shall be given to the Parties at their respective
addresses set forth on the signature page hereto and shall be sent by (a) hand delivery, (b) a recognized overnight delivery service
or (c) e-mail. Notices sent by hand delivery shall be deemed received when delivered; notices sent by overnight delivery service shall
be deemed received on the next business day and notices sent by electronic mail when sent if sent during normal business hours of the
recipient and confirmed, and if not so confirmed, then on the next business day.
- 9 -
6.16 Expenses.
VSee Health and Chen shall each pay its respective expenses, fees and costs incident to the preparation and execution of this Agreement
and, except as otherwise expressly provided for herein, each Party shall bear its respective expenses or fees involved in the preparation
and delivery of all documents required to be delivered by or on behalf of such Party hereunder, whether or not the transactions contemplated
hereunder are consummated.
6.17 Severability.
The invalidity or unenforceability of any provision hereof shall in no way effect the validity or enforceability of any other provision.
6.18 Specific
Performance. The Parties acknowledge that irreparable harm would occur in the event that any provision of this Agreement were not
performed in accordance with its specific terms. Accordingly, each Party shall be entitled to seek injunctive relief and specific performance
to enforce the terms of this Agreement, in addition to any other remedies available at law or in equity.
6.19 Interpretation.
No provision of this Agreement or any agreement ancillary hereto shall be interpreted or construed against any Party because that Party
or his or its legal representative drafted such provision. Any pronoun used in this Agreement shall be deemed to include singular and
plural and masculine, feminine and neuter gender, as the case may be.
[The
Remainder of This Page is Intentionally Blank; Signature Page(s) Follow]
- 10 -
IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date and year first written above.
VSEE
HEALTH, INC.
By:
/s/ Imoigele Aisiku
Name:
Imoigele
Aisiku
Title:
Chief
Executive Officer
Address
for Notice:
980
N. Federal Hwy, Suite 304
Boca
Raton, Florida 33432
With
a copy (which shall not constitute notice) to:
Pryor
Cashman LLP
c/o
M. Ali Panjwani
7
Times Square
New
York, New York 10036
E-mail:
ali.panjwani@pryorcashman.com
CHEN
/s/ Milton Chen
Milton
Chen
Address
for Notice:
6102
Rainbow Dr.
San
Jose, California 95129
With
a copy (which shall not constitute notice) to:
Castor
Easton LLP
c/o
Tyler B. Wilson, Esq.
47
South Pennsylvania Street, Suite 700
Indianapolis,
Indiana 46204
E-mail:
twilson@castoreaston.com
- 11 -
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: vseeex99-1.htm · Sequence: 3
Exhibit
99.1
VSEE
HEALTH, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On
May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase
Agreement”) with Milton Chen, the Company’s co-Chief Executive Officer and Chairman of the Board and the Chief Executive
Officer of VSee Lab, Inc., a Delaware Corporation and wholly-owned subsidiary of the Company (“VSee Lab”). Pursuant to the
Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell to Mr. Chen, on the May 31, 2026 (the “Closing
Date”), all of the equity securities of VSee Lab (the “VSee Lab Stock”), free and clear of all liens and encumbrances.
Under the Purchase Agreement, Mr. Chen is solely responsible for causing the Company to satisfy any and all indebtedness and other liabilities
of VSee Lab that are not paid as of the closing contemplated by the Purchase Agreement (the “Closing”) and the Company will
have no obligation with respect thereto. Notwithstanding, the Company will retain, pay, perform and discharge and remain solely responsible
for, any and all liabilities, obligations or commitments of VSee Lab or relating to the ownership or operation of VSee Lab related to
any period, event, circumstance or condition occurring prior to the Closing Date, including any liabilities relating to taxes for any
and all taxes attributable to any taxable period ending on or before the Closing Date and the portion through the Closing Date for any
taxable period that includes, but does not end, on the Closing Date, other than sales and use taxes accrued at the company level, which
will remain an obligation of VSee Lab, regardless of the time period of when such obligation were incurred and except to the extent expressly
assumed by Mr. Chen pursuant to the Purchase Agreement.
In
consideration for the VSee Lab Stock and the mutual release of liability set forth in the Purchase Agreement, Mr. Chen has agreed to
transfer to the Company all of the common stock, par value $0.0001 per share (the “Common Stock”), of the Company that he
currently owns, or 2,870,069 shares of Common Stock. In connection with the execution of the Purchase Agreement, Mr. Chen resigned as
co-Chief Executive Officer and chairman of the board of directors of the Company, effective as of the Closing Date.
The
following unaudited pro forma condensed consolidated balance sheet as of March 31, 2026, is presented as if the Transaction, as described
in the notes to these unaudited pro forma condensed consolidated financial statements, had occurred on March 31, 2026.
The
unaudited pro forma condensed consolidated statements of operations for the three months ended March 31, 2026, and the year ended December
31, 2025, are presented as if the Transaction had occurred on January 1, 2025. All adjustments shown in the unaudited
pro
forma condensed consolidated financial statements are transaction accounting adjustments.
The
unaudited pro forma condensed consolidated financial statements were prepared in accordance with Article 11 of Regulation S-X. Such unaudited
pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative
of the results of operations that would have been achieved had the events reflected been completed as of the dates indicated or of the
results that may be obtained in the future. The unaudited pro forma condensed consolidated statement of operations is based on management’s
estimate of the effects on the financial statements of the Transaction. Pro forma adjustments are based on currently available information,
historical results and certain assumptions that management believes are reasonable and are described in the accompanying notes.
VSEE
HEALTH, INC.
UNAUDITED
PROFORMA CONDENSED CONSOLIDATED BALANCE SHEET
AS
OF MARCH 31, 2026
Historical
(Unaudited)
Pro forma adjustment
Pro forma
ASSETS
Current assets
Cash
$ 1,346,132
$ (101,616 )
(f)
$ 1,244,516
Accounts receivable, net of allowance for credit losses of $1,190,801 as of March 31, 2026
2,671,169
(298,705 )
(f)
2,372,464
Due from related party
312,947
-
312,947
Prepaids and other current assets
511,051
(145,042 )
366,009
Total current assets
4,841,299
(545,363 )
4,295,936
Non-current assets
Long-term investments
749,800
-
749,800
Right-of-use assets, net
10,881
-
10,881
Intangible assets, net
8,232,500
-
8,232,500
Goodwill
4,916,694
-
4,916,694
Fixed assets, net
265,245
(60,151 )
(f)
205,094
Total assets
$ 19,016,419
$ (605,514 )
$ 18,410,905
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities
$ 8,529,725
$ (2,216,512 )
(f)
$ 6,313,213
Deferred revenue
1,446,585
(1,446,585 )
(f)
-
Due to related party
51,900
-
51,900
Operating lease liabilities
10,881
-
10,881
Encompass Purchase Liability
400,000
-
400,000
Convertible Note, at fair value
346,943
-
346,943
Loan payable, related party
471,651
(330,000 )
(f)
141,651
Notes payable, net of discount
524,093
-
524,093
Common stock issuance obligation
12,798
-
12,798
Total current liabilities
$ 11,794,576
$ (3,993,097 )
$ 7,801,479
Non-current liabilities
Notes payable, less current portion, net of discount
781,581
-
781,581
Deferred tax liability
119,192
-
119,192
Total liabilities
$ 12,695,349
$ (3,993,097 )
$ 8,702,252
STOCKHOLDERS’ EQUITY
Series A Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 422 shares issued and outstanding as of March 31, 2026
1
-
1
Series B Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 2,000 shares issued and outstanding as of March 31, 2026
1
-
1
Common stock, $0.0001 par value; 100,000,000 shares authorized 44,429,352 shares issued and outstanding as of March 31, 2026
4,730
-
4,730
Treasury stock, at cost; 2,870,069 shares held as of March 31, 2026
-
(545,313 )
(e)
(545,313 )
Additional paid-in capital
91,333,323
-
91,333,323
Accumulated deficit
(85,016,985 )
3,932,896
(f)
(81,084,089 )
Total stockholders’ equity
6,321,070
3,387,583
9,708,653
Total liabilities and stockholders’ equity
$ 19,016,419
$ (605,514 )
$ 18,410,905
2
VSEE
HEALTH, INC.
UNAUDITED
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE THREE MONTHS ENDED MARCH 31, 2026
Historical
Pro
forma adjustment
Pro
Forma
Revenues
Subscription
fees
$ 605,470
$ (605,470 )
(a)
$ -
Professional
services and other fees
606,745
(606,745 )
(a)
-
Technical
engineering fees
68,677
(68,677 )
(a)
-
Patient
fees
881,340
-
881,340
Telehealth
fees
997,953
-
997,953
Total
revenues
3,160,185
(1,280,892 )
1,879,293
Cost
of revenues
1,962,074
(810,194 )
(a)
1,151,880
Gross
margin
1,198,111
(470,698 )
727,413
-
Operating
expenses
-
Compensation
and related benefits
1,732,003
(1,482,984 )
(b)
249,019
General
and administrative
2,440,383
(302,452 )
(b)
2,137,931
Total
operating expenses
4,172,386
(1,785,436 )
2,386,950
Net
operating loss
(2,974,275 )
1,314,738
(1,659,537 )
-
Other
income (expense)
-
Interest
expense
(113,098 )
21,155
(b)
(91,943 )
Change
in fair value of financial instruments
143,040
-
143,040
Gain
on extinguishment of financial liabilities
367,809
-
367,809
Total
other income (expense), net
397,751
21,155
418,906
Loss
before provision for income taxes
(2,576,524 )
(1,335,893 )
(1,240,631 )
Provision
for income taxes
(23,738 )
(513 )
(d)
(24,251 )
Net
loss
$ (2,600,262 )
$ (1,355,380 )
$ (1,264,882 )
Basic
and diluted loss per common share
$ (0.05 )
$ -
$ (0.03 )
Weighted
average number of common shares outstanding, basic and diluted
47,902,512
-
45,032,443
3
VSEE
HEALTH, INC.
UNAUDITED
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE YEAR ENDED DECEMBER 31, 2025
Historical
(Audited)
Pro forma adjustment
Pro Forma
Revenues
Subscription fees
$ 3,230,239
$ (3,230,239 )
(a)
$ -
Professional services and other fees
3,042,688
(3,042,398 )
(a)
290
Technical engineering fees
1,042,593
(1,042,593 )
(a)
-
Patient fees
3,377,536
-
3,377,536
Telehealth fees
3,922,628
-
3,922,628
Institutional fees
2,500
-
2,500
Total revenues
14,618,184
(7,315,230 )
7,302,954
Cost of revenues
7,262,219
(3,901,878 )
(a)
3,360,341
Gross margin
7,355,965
(3,413,352 )
3,942,613
Operating expenses
Compensation and related benefits
6,901,583
(4,220,844 )
(b)
2,680,739
General and administrative
10,037,275
(1,272,967 )
(b)
8,764,308
Total operating expenses
16,938,858
(5,493,811 )
11,445,047
Net operating loss
(9,582,893 )
2,080,459
(7,502,434 )
Other income (expense)
Interest expense
(2,811,861 )
85,796
(b)
(2,897,665 )
Other income (expense), net
47,429
(15,429 )
(b)
62,858
Change in fair value of financial instruments
(1,450,271 )
-
(1,450,271 )
Loss on extinguishment of loan
(221,202 )
-
(221,202 )
Loss on issuance of financial instrument
(668,020 )
-
(668,020 )
Gain on disposal of subsidiaries
-
2,599,736
(c)
2,599,736
Total other income (expense), net
(5,061,531 )
2,670,103
(2,574,564 )
Loss before benefit from (provision for) income taxes
(14,644,424 )
4,750,562
(10,076,998 )
Provision for income taxes
(68,426 )
(35,823 )
(d)
(104,249 )
Net loss
$ (14,712,850 )
$ 4,786,385
$ (9,972,749 )
Basic and diluted loss per common share
$ (0.73 )
$ -
$ (0.58 )
Weighted average number of common shares outstanding, basic and diluted
20,143,393
-
17,273,324
4
VSEE
HEALTH, INC.
NOTES
TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Note
1 - Basis of Presentation
The
unaudited pro forma consolidated balance sheet and statements of operations are based upon the historical consolidated financial statements
of VSee Health, Inc. (the “Company”), which were included in its Quarterly Report on Form 10-Q for the three months ended
March 31, 2026, and its Annual Report on Form 10-K for the year ended December 31, 2025. Unless the context indicates otherwise, any
reference in this report to the “Company,” “we,” “us,” and “our” refers to VSee Health,
Inc.
The
unaudited pro forma condensed consolidated statements of operations reflect the disposal of the Company’s wholly owned subsidiary,
VSee Lab, Inc, as if the disposal had been consummated on January 1, 2025. The unaudited pro forma condensed consolidated balance sheet
as of March 31, 2026, reflect such sale as if it had been consummated on that date.
Note
2 – Pro Forma Adjustments
(a)
This adjustment reflects the elimination of revenues and cost of revenues of VSee Labs and it’s 100% subsidiary i.e. This American
Doc, Inc. (“TAD”).
(b)
This adjustment reflects the elimination of operating expenses and other income (expense), net of the VSee Labs and TAD business.
(c)
This adjustment reflects the gain arising from the transaction as of May 31, 2026.
(d)
This adjustment represents the estimated income tax effect of the pro-forma adjustments. The tax effect of the pro-forma adjustments
was calculated using the historical statutory rates in effect for the periods presented.
(e)
This adjustment represents the consideration in the form of stock repurchase at the closing of the transaction.
(f)
These adjustments reflect the elimination of assets and liabilities attributable to VSee Lab, Inc.
5
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Cover
May 31, 2026
Document Type
8-K
Amendment Flag
false
Document Period End Date
May 31, 2026
Entity File Number
001-41015
Entity Registrant Name
VSEE
HEALTH, INC.
Entity Central Index Key
0001864531
Entity Tax Identification Number
86-2970927
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
980
N Federal Hwy #304
Entity Address, City or Town
Boca Raton
Entity Address, State or Province
FL
Entity Address, Postal Zip Code
33432
City Area Code
(561)
Local Phone Number
672-7068
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
Common Stock, $0.0001 par value per share
Title of 12(b) Security
Common
Stock, $0.0001 par value per share
Trading Symbol
VSEE
Security Exchange Name
NASDAQ
Warrants, which entitles the holder to purchase one (1) share of common stock at a price of $11.50 per whole share
Title of 12(b) Security
Warrants,
which entitles the holder to purchase one (1) share of common stock at a price of $11.50 per whole share
Trading Symbol
VSEEW
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=VSEE_CommonStock0.0001ParValuePerShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type:
X
- Details
Name:
us-gaap_StatementClassOfStockAxis=VSEE_WarrantsWhichEntitlesHolderToPurchaseOne1ShareOfCommonStockAtPriceOf11.50PerWholeShareMember
Namespace Prefix:
Data Type:
na
Balance Type:
Period Type: